Breaking News Instant updates and real-time market news.

VRTX

Vertex

$166.76

-2.82 (-1.66%)

08:13
09/30/19
09/30
08:13
09/30/19
08:13

Vertex, Ribometrix establish strategic collaboration

Vertex Pharmaceuticals and RNA therapeutics developer Ribometrix, announced today that the companies have entered into a strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The collaboration will combine Ribometrix's proprietary discovery platform for identifying and optimizing small molecule therapeutics that modulate RNA function by targeting three-dimensional RNA structures with Vertex's scientific, clinical and regulatory capabilities for up to three therapeutic programs, including one ongoing discovery program from Ribometrix. Under the terms of the agreement, Vertex will pay Ribometrix approximately $20M upfront, which includes an equity investment in the company. Initially, Ribometrix will undertake two discovery programs with Vertex, and Vertex has an option to add a third program. Following discovery and optimization of novel therapeutic molecules, Vertex has the option to take an exclusive global license for the development and commercialization of molecules for that program. Ribometrix is eligible to receive more than $700M in total potential payments based upon the successful achievement of specified research, development, regulatory and commercial milestones as part of the collaboration. In addition, Vertex will pay tiered royalties on future net global sales on any products that result from the collaboration.

  • 19

    Mar

VRTX Vertex
$166.76

-2.82 (-1.66%)

08/28/19
PIPR
08/28/19
NO CHANGE
PIPR
Symdeko deaths in FDA database likely due to disease, says Piper Jaffray
08/28/19
PIPR
08/28/19
NO CHANGE
Target $230
PIPR
Overweight
Vertex drug not cited as cause of 30 deaths in FDA database, says Piper Jaffray
The FDA Adverse Events Reporting System Public Dashboard citing 30 deaths with Symdeko caused volatility today in shares of Vertex Pharmaceuticals, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. After accessing the website, the analyst says none of the 30 deaths specifically indicate Symdeko, "but rather appear to be due to underlying cystic fibrosis disease." As such, the FAERS report does not signify a unique problem with Symdeko or Vertex's TripleRx combination, which is under review at the FDA, contends Tenthoff. The "timing of this short rumor to be suspicious during a quiet, end of summer week," he adds. The analyst continues to forecast Vertex's total cystic fibrosis sales at $3.7B this year, growing to $5B in 2020 with the TripleRx launch. He reiterates an Overweight rating on the stock with a $230 price target. Vertex in late morning trading is up 1%, or $1.84, to $180.09.
09/03/19
GSCO
09/03/19
UPGRADE
Target $254
GSCO
Conviction Buy
Vertex upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter added Vertex Pharmaceuticals to his firm's Americas Conviction List while raising his price target for the shares to $254 from $226 and keeping a Buy rating on the name. Vertex is in the midst of a multi-year period of "rapid" margin expansion and earnings outperformance driven by growth of the legacy cystic fibrosis franchise and likely launch of VX-445 triple combination, which has a March 19 FDA action date, Richter tells investors in a research note. Further, the analyst believes investor attention should now shift to the company's emerging pipeline, where he sees a "significant opportunity" in the Phase 2-ready alpha-1 antitrypsin deficiency disorder program.
09/23/19
JEFF
09/23/19
NO CHANGE
Target $220
JEFF
Buy
Vertex price target raised to $220 from $210 at Jefferies
Jefferies analyst Michael Yee raised his price target for Vertex Pharmaceuticals to $220 from $210 and reiterates a Buy rating on the shares. Potential early approval of the company's cystic fibrosis triple combo and a strong launch set up consensus to raise near-term numbers, Yee tells investors in a research note. Next year "starts to be all about the pipeline," with up to six programs that reflect $1B-$5B in potential new revenues, says the analyst. He believes Vertex "could have a big inflection in 2020-2021 as it goes from one big blockbuster to the next."

TODAY'S FREE FLY STORIES

PFE

Pfizer

$36.91

-0.13 (-0.35%)

06:47
11/12/19
11/12
06:47
11/12/19
06:47
Hot Stocks
Pfizer says Phase 3 study of XELJANZ met primary endpoint »

Pfizer announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 22

    Nov

  • 07

    Dec

VOD

Vodafone

$20.56

-0.12 (-0.58%)

06:46
11/12/19
11/12
06:46
11/12/19
06:46
Earnings
Vodafone reports 1H revenue EUR21.94B vs. EUR21.85B last year »

H1 organic service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

MMC

Marsh & McLennan

$103.45

0.14 (0.14%)

06:46
11/12/19
11/12
06:46
11/12/19
06:46
Initiation
Marsh & McLennan initiated  »

Marsh & McLennan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAA

IAA

$38.89

0.75 (1.97%)

06:46
11/12/19
11/12
06:46
11/12/19
06:46
Earnings
IAA reports Q3 adjusted EPS 35c, consensus 33c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ALL

Allstate

$109.36

1.205 (1.11%)

06:45
11/12/19
11/12
06:45
11/12/19
06:45
Initiation
Allstate initiated  »

Allstate assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,771.70

-13.65 (-0.76%)

06:45
11/12/19
11/12
06:45
11/12/19
06:45
Periodicals
Some of Amazon's Chinese sellers are cause for concern for consumers, WSJ says »

Amazon's China…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

APOG

Apogee Enterprises

$38.48

(0.00%)

06:44
11/12/19
11/12
06:44
11/12/19
06:44
Hot Stocks
Apogee Enterprises announces Cooperation Agreement with Engaged Capital »

Apogee Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNVVY

ConvaTec

$0.00

(0.00%)

06:42
11/12/19
11/12
06:42
11/12/19
06:42
Initiation
ConvaTec initiated  »

ConvaTec re-initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SE

Sea Limited

$30.97

-0.74 (-2.33%)

06:42
11/12/19
11/12
06:42
11/12/19
06:42
Earnings
Sea Limited raises FY19 adjusted revenue view to $1.7B-$1.8B from $1.6B-$1.7B »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SFIX

Stitch Fix

$20.90

-0.95 (-4.35%)

06:41
11/12/19
11/12
06:41
11/12/19
06:41
Recommendations
Stitch Fix analyst commentary  »

Stitch Fix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSNUY

Fresenius SE

$0.00

(0.00%)

06:41
11/12/19
11/12
06:41
11/12/19
06:41
Initiation
Fresenius SE initiated  »

Fresenius SE re-initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLR

Fluor

$18.88

0.075 (0.40%)

, XOM

Exxon Mobil

$70.29

-0.5 (-0.71%)

06:41
11/12/19
11/12
06:41
11/12/19
06:41
Hot Stocks
Fluor poised to deliver Esso Fawley Strategy Project in UK for Exxon Mobil »

Fluor (FLR) announced…

FLR

Fluor

$18.88

0.075 (0.40%)

XOM

Exxon Mobil

$70.29

-0.5 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SE

Sea Limited

$30.97

-0.74 (-2.33%)

06:40
11/12/19
11/12
06:40
11/12/19
06:40
Earnings
Breaking Earnings news story on Sea Limited »

Sea Limited reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DVA

DaVita

$69.38

-0.47 (-0.67%)

06:39
11/12/19
11/12
06:39
11/12/19
06:39
Initiation
DaVita initiated  »

DaVita re-initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCC

Ares Capital

$18.54

0.025 (0.14%)

06:39
11/12/19
11/12
06:39
11/12/19
06:39
Initiation
Ares Capital initiated  »

Ares Capital resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SURF

Surface Oncology

$1.63

-0.11 (-6.32%)

06:38
11/12/19
11/12
06:38
11/12/19
06:38
Earnings
Surface Oncology reports Q3 EPS (61c), consensus (58c) »

"The Surface…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

SNN

Smith & Nephew

$42.29

-0.19 (-0.45%)

06:38
11/12/19
11/12
06:38
11/12/19
06:38
Initiation
Smith & Nephew initiated  »

Smith & Nephew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$56.60

0.58 (1.04%)

06:38
11/12/19
11/12
06:38
11/12/19
06:38
Recommendations
Applied Materials analyst commentary  »

Applied Materials price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 09

    Dec

  • 09

    Dec

LIN

Linde plc

$202.33

-0.67 (-0.33%)

06:37
11/12/19
11/12
06:37
11/12/19
06:37
Earnings
Linde plc raises FY19 adj. EPS to $7.25-$7.30 from $6.95-$7.18, consensus $7.12 »

This range includes an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SAGE

Sage Therapeutics

$144.37

-2.25 (-1.53%)

06:36
11/12/19
11/12
06:36
11/12/19
06:36
Hot Stocks
Sage Therapeutics sees end of year balance of $950M in cash and equivalents. »

Based on its current…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ATV

Acorn International

$17.90

0.4 (2.29%)

06:35
11/12/19
11/12
06:35
11/12/19
06:35
Hot Stocks
Acorn International to sell Zhuhai Acorn for $1.45M in cash »

Acorn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$144.37

-2.25 (-1.53%)

06:35
11/12/19
11/12
06:35
11/12/19
06:35
Earnings
Sage Therapeutics reports Q3 EPS ($3.48), consensus ($3.36) »

Reports Q3 revenue $3.6M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LIN

Linde plc

$202.33

-0.67 (-0.33%)

06:35
11/12/19
11/12
06:35
11/12/19
06:35
Earnings
Linde plc reports Q3 adj. EPS $1.94, consensus $1.78 »

Reports Q3 revenue $7B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DHI

D.R. Horton

$52.65

1.535 (3.00%)

06:35
11/12/19
11/12
06:35
11/12/19
06:35
Hot Stocks
D.R. Horton reports Q4 Homes closed increased 9% to 16,024 homes »

Q4 homes closed increased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DHI

D.R. Horton

$52.65

1.535 (3.00%)

06:33
11/12/19
11/12
06:33
11/12/19
06:33
Earnings
D.R. Horton sees FY20 revenue $18.5B-$19B, consensus $18.58B »

Sees FY20: Homes closed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.